Systemic inhibition of VEGF levels following intravitreal anti-VEGF administration in patients with proliferative retinopathies is particularly concerning in preterm infants with ROP and incomplete vascular development of many organs [139,140,141,142,143,144], as VEGF is an important factor to maintain normal neuronal and vascular function. The gene discussed is VEGFA; the disease is retinopathy of prematurity.